Latest News
From the Journals
Topical fluorouracil reduces risk for surgery for SCC
The study results indicate that topical fluorouracil 5% could be used to reduce the risk of squamous cell carcinoma in high-risk patients.
Conference Coverage
Sorafenib plus chemo prolongs event-free survival in AML
ATLANTA – Updated results from the phase 2 SORAML trial support the addition of sorafenib in younger adults with newly diagnosed AML.
Conference Coverage
Trial updates will help tailor endocrine therapy for premenopausal breast cancer
SAN ANTONIO – In an updated joint analysis of TEXT and SOFT, benefit of AI plus OFS over tamoxifen plus OFS was sustained, with a 4.0% absolute...
Feature
Massachusetts named healthiest state for 2017
Mississippi, on the other hand, has the most room for improvement.
Conference Coverage
New and improved classifiers may sharpen thyroid nodule diagnosis
VICTORIA, B.C. – The tests could improve preoperative assessment, even in histologic subsets that pose diagnostic challenges.
Conference Coverage
How to manage cytokine release syndrome
ATLANTA – Don’t wait to give anticytokine therapy.
Conference Coverage
New tool predicts late distant recurrence of postmenopausal ER+ breast cancer
SAN ANTONIO – CTS5 was validated among 11,446 postmenopausal women treated for ER+ breast cancer who had had 5 years of adjuvant endocrine therapy...
News
FDA expands indication for bosutinib in newly diagnosed CML
The new indication includes treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome–positive CML.
Conference Coverage
EndoPredict results reflected tumor response to neoadjuvant therapy
SAN ANTONIO – The results of the EndoPredict test appear to predict tumor response in patients with early hormone receptor–positive, HER2-negative...
Conference Coverage
Wider margins may reduce recurrence risk in early breast cancer
SAN ANTONIO – Updated analysis fails to confirm that ‘no-tumor on ink’ is optimal.
Conference Coverage
Enzalutamide plus exemestane improves PFS in HR+ breast cancer subset
SAN ANTONIO – The combo improved outcomes in those who had not received prior endocrine therapy and who were positive for androgen receptor...